1061 Stock Overview
An investment holding company, develops, manufactures, distributes, and sells bio-pharmaceutical products in the People’s Republic of China, Hong Kong, and internationally.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 3/6 |
Financial Health | 6/6 |
Dividends | 4/6 |
Essex Bio-Technology Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$2.32 |
52 Week High | HK$3.15 |
52 Week Low | HK$1.96 |
Beta | 0.20 |
11 Month Change | -2.11% |
3 Month Change | -9.02% |
1 Year Change | -24.68% |
33 Year Change | -64.58% |
5 Year Change | -53.69% |
Change since IPO | 134.34% |
Recent News & Updates
Essex Bio-Technology's (HKG:1061) Upcoming Dividend Will Be Larger Than Last Year's
Aug 29Essex Bio-Technology Limited's (HKG:1061) Low P/E No Reason For Excitement
May 06Recent updates
Essex Bio-Technology's (HKG:1061) Upcoming Dividend Will Be Larger Than Last Year's
Aug 29Essex Bio-Technology Limited's (HKG:1061) Low P/E No Reason For Excitement
May 06Calculating The Fair Value Of Essex Bio-Technology Limited (HKG:1061)
Mar 21Essex Bio-Technology (HKG:1061) Has A Pretty Healthy Balance Sheet
Dec 07Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly
Dec 07Essex Bio-Technology (HKG:1061) Is Due To Pay A Dividend Of HK$0.04
Aug 25Is Essex Bio-Technology (HKG:1061) Using Too Much Debt?
Jun 22Essex Bio-Technology (HKG:1061) Has Announced That It Will Be Increasing Its Dividend To HK$0.055
May 02Essex Bio-Technology (HKG:1061) Will Pay A Larger Dividend Than Last Year At HK$0.055
Mar 30Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly
Jun 29Is Essex Bio-Technology (HKG:1061) A Risky Investment?
Mar 31If You Had Bought Essex Bio-Technology (HKG:1061) Stock Five Years Ago, You Could Pocket A 40% Gain Today
Mar 13How Many Essex Bio-Technology Limited (HKG:1061) Shares Did Insiders Buy, In The Last Year?
Feb 15Do Institutions Own Essex Bio-Technology Limited (HKG:1061) Shares?
Jan 25Essex Bio-Technology Limited's (HKG:1061) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?
Jan 04Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly
Dec 13Why Essex Bio-Technology's (HKG:1061) CEO Pay Matters
Nov 23Shareholder Returns
1061 | HK Biotechs | HK Market | |
---|---|---|---|
7D | 1.3% | 0.6% | -2.7% |
1Y | -24.7% | -24.8% | 0.006% |
Return vs Industry: 1061 matched the Hong Kong Biotechs industry which returned -24.8% over the past year.
Return vs Market: 1061 underperformed the Hong Kong Market which returned 0% over the past year.
Price Volatility
1061 volatility | |
---|---|
1061 Average Weekly Movement | 4.0% |
Biotechs Industry Average Movement | 7.0% |
Market Average Movement | 6.4% |
10% most volatile stocks in HK Market | 13.2% |
10% least volatile stocks in HK Market | 3.3% |
Stable Share Price: 1061 has not had significant price volatility in the past 3 months.
Volatility Over Time: 1061's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1990 | 1,459 | Haizhou Fang | www.essexbio.com |
Essex Bio-Technology Limited, an investment holding company, develops, manufactures, distributes, and sells bio-pharmaceutical products in the People’s Republic of China, Hong Kong, and internationally. The company operates through Ophthalmology and Surgical segments. It researches and develops therapeutic fibroblast growth factor products for the treatment of cellular proliferation, differentiation, and migration.
Essex Bio-Technology Limited Fundamentals Summary
1061 fundamental statistics | |
---|---|
Market cap | HK$1.33b |
Earnings (TTM) | HK$262.89m |
Revenue (TTM) | HK$1.62b |
5.0x
P/E Ratio0.8x
P/S RatioIs 1061 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
1061 income statement (TTM) | |
---|---|
Revenue | HK$1.62b |
Cost of Revenue | HK$165.38m |
Gross Profit | HK$1.45b |
Other Expenses | HK$1.19b |
Earnings | HK$262.89m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.46 |
Gross Margin | 89.78% |
Net Profit Margin | 16.24% |
Debt/Equity Ratio | 15.2% |
How did 1061 perform over the long term?
See historical performance and comparisonDividends
5.2%
Current Dividend Yield23%
Payout RatioDoes 1061 pay a reliable dividends?
See 1061 dividend history and benchmarksEssex Bio-Technology dividend dates | |
---|---|
Ex Dividend Date | Sep 06 2024 |
Dividend Pay Date | Sep 24 2024 |
Days until Ex dividend | 1 day |
Days until Dividend pay date | 19 days |
Does 1061 pay a reliable dividends?
See 1061 dividend history and benchmarks